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ABSTRACT 
 
KARA FOWLER: Dereplication and Prioritization of Natural Product Extracts for 
Antifungal Drug Discovery 
(Under the direction of Melissa Jacob) 
 
 
 The prevalence of opportunistic fungal infections in hospital settings are at 
alarming rates. Through technological advances in natural product research, plants have 
become a useful source for antifungal drug discovery. More samples can be screened at 
once, fractionated in less time, and biologically tested at smaller quantities. However, 
isolating antifungal compounds from these plant extracts and determining their specific 
chemical makeup can still take up a significant amount of time. Therefore, this thesis 
presents a prioritization technique to prevent the need to isolate every compound within 
an active fraction. With the guidance of literature research on the genus and species of 
each plant sample coupled with the biological activity data collected on each sample, 
plant extracts can be prioritized for isolation efforts or thrown out completely if found 
uninteresting. This method of prioritization also fuels dereplication efforts by preventing 
researchers from spending time and resources on plants that have already been worked 
on. Plants that have had little work done on them and that have highly active fractions 
will lead to the discovery of novel antifungal drugs. 
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Introduction 
Natural products have been used for medicinal purposes dating back to 2600 BCE 
in Mesopotamia (Newman et al. 2007). Many plants and herbs were used for headaches, 
wounds, indigestion, and other everyday ailments. Records show that Artemisia annua 
was used in China, snakeroot plant in India, coca bush in Mesoamerica, opium poppy in 
Egypt, and many other natural products around the world. The most extensive record is 
the “Ebers Papyrus” from Egypt in 1500 BCE, listing over seven hundred drugs that were 
mostly derived from plants (Newman et al. 2007). Plants have been so widely used as 
medicines because they are so accessible, renewable, and plentiful (Mishra and Tiwari 
2011). In recent decades, researchers have studied what components of these plants 
provide activity against diseases and infection. Natural products are an immense resource 
for compounds with a tremendous amount of functional and chemical diversity (Tu et al. 
2010).  
Opportunistic fungal infections can be fatal to patients with compromised 
immunities, including cancer patients, transplant recipients, and those who have 
contracted human immunodeficiency virus / acquired immunodeficiency syndrome 
(HIV/AIDS). The most common pathogenic fungal species is Candida which now makes 
up 8-9% of all bloodstream infections and has a high fatality rate of up to 40% which is 
unacceptable with today’s medicinal technology. The prevalence of these life-threatening 
infections in hospital settings has reached alarming rates and there is a growing need for 
more effective and extensive antifungal drugs. There are only three types of antifungal 
drugs in use today: those that that target the cell membrane (polyenes, e.g. Amphotericin 
B), those that inhibit ergosterol biosynthesis (azoles, e.g. Fluconazole), and those that 
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target biosynthesis of the cell wall (echinocandins, e.g. Caspofungin). However each of 
these classes of antifungal drugs has serious curative limitations. Amphotericin B has 
significant toxicity, some species of fungi can develop drug resistance to azoles, and 
echinocandins can only be administered to a patient intravenously (Roemer et al. 2011).  
In the past twenty years, natural product research efforts in the discovery of new 
antifungal drugs have died down due to the complexity and significant time consumption 
of isolating active compounds. It can take up to several months to perform a primary 
screening of crude plant extracts, fractionate the extract based on bioassay results, purify 
the active compound(s), and determine the exact chemical structure of isolated 
compounds. However, new technological advances in high-throughput screening (HTS) 
have allowed for more samples to be screened at one time and at smaller quantities, 
saving time and resources. Recent developments in analytical and automation 
technologies have improved the speed at which samples are fractionated and processed. 
These innovations have allowed for a new opportunity to re-establish natural products as 
a source for novel drug discoveries (Tu et al. 2010).  
Even though modern technology has improved drug discovery immensely, natural 
product extracts can cause complications themselves. First of all, polyphenols (vegetable 
tannins), can elicit false-positives in enzymatic and cellular screening methods because of 
their promiscuous enzyme inhibition and alterations in the cells’ redox potential. 
Polyphenols can be found at significant concentrations in ethanol extracts of plants. A 
second problem arises in the chemical diversity of a single plant extract. This extract’s 
chemical composition may contain various classes of chemicals that often display 
different biological activities which can sometimes oppose each other. Finally, 
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compounds that are biologically active may be present in crude plant extracts but may be 
at immeasurably low concentrations and therefore do not show bioactivity during 
screening. Various research teams have attempted to eliminate these problems with plant 
extracts (Tu et al. 2010). 
Saint Jude Children’s Research hospital in Memphis, Tennessee, in collaboration 
with the National Center for Natural Products Research (NCNPR) at the University of 
Mississippi, has proposed a more efficient high-resolution and high-throughput 
fractionation strategy to limit natural product complications. Plants from around the 
world were collected, extracted, and fractionated using a high-throughput fractionation 
procedure to generate thousands of fractions. These fractions were also evaluated 
chemically by analyzing them via liquid chromatography-mass spectrometry (LC-MS), 
which determines the chemical make-up of the fraction by molecular weight and ultra 
violet (UV) absorption characteristics. These fractions were then evaluated for their 
ability to inhibit the growth of a panel of pathogenic bacteria and fungi. Fractions that 
showed significant anti-infective activity were then selected for LC-MS analysis. 
 
Experimental 
Plants were collected, delivered to NCNPR, freeze dried, and ground. Once 
ground they were indexed by GPS, genus and species, geographic location, plant part, 
collector, date, and voucher species storage. Each ground sample was transferred to a 
specific Accelerated Solvent Extraction (ASE) cell was filled with 95% ethanol and 
pressurized to 1500 psi at 40°C. A ten minute long static period was used to extract plant 
compounds, and the sample was then flushed full with 95% ethanol. The cell was then 
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purged of all liquid for 120 seconds. This process was then repeated two more times for 
each sample. The combined plant extracts were dried completely with the use of a 
Speedvac or a Genevac. The dried extracts were then provided to St. Jude Children’s 
Research Hospital in Memphis, Tennessee. 
Once the dried samples arrived at St. Jude, polyphenols were removed through the 
use of a 700 mg polyamide-filled cartridge and a 48-place positive-pressure solid-phase 
extraction (SPE) manifold. The ethanol extracts, which were each around 100 mg, were 
dissolved and transferred onto a polyamide SPE cartridge. Five column volumes of 
methanol were then used to rinse the column. A Zymark TurboVap LV Concentration 
Workstation produced a stream of nitrogen to dry the collected effluent.  
 Following prefractionation, samples were dissolved in 2 mL of dimethyl 
sulfoxide (DMSO). Each sample was separated into 24 fractions and collected in 16 x 
100 mm preweighed glass tubes. The preparative high-performance liquid 
chromatography (HPLC) separations were performed on a Gemini 5 μm C18 110A 
column. A Shimadzu LC-8A binary preparative pump with a Shimadzu SCL-10A VP 
system controller was connected to the Gilson 215 auto sampler and Gilson 215 fraction 
collector. Detections were obtained with a Shimadzu SPD-M20A diode-array detector 
and a Shimadzu ELSD-LT II evaporative light scattering detector. The mobile phase was 
composed of water (A) and methanol (B): 0 min, 98:2; 0.5 min, 98:2; 6.5 min, 0:100; 
12.3 min, 0:100; 12.5 min, 98:2; 12.95 min, stop. 25 mL/min was the flow rate. 
A GeneVac HT series II high-performance solvent evaporation system was used 
to dry the collected fractions. The chamber was preheated to and remained at 35 °C. The 
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SampleGuard Control temperature was set at 40 °C, and the CoolHeat Enable pressure 
was set at 40 mbar. 
The fraction-collection tubes were preweighed with a Bohdan BA-200 Balance 
Automator and were positioned on a custom Gilson 207 test tube rack. Then, tubes 
containing natural product fractions were reweighed with the Bohdan BA-200. A FWA 
program developed on a Pipeline Pilot platform was used to calculate the net weight of 
each fraction using the difference between the two weights. 
The natural product plant fractions were plated using a Freedom Evo Tecan 
system. Samples in GeneVac racks were dissolved in the suitable plating solvent. The 
dissolved samples were transferred onto 384-well plates for ultra performance liquid 
chromatography-mass spectrometry (UPLC-MS) analysis. 
The final quality control (QC) of the natural product fractions was achieved with 
the use of a Waters Acquity UPLC-MS system, using a Waters Acquity UPLC system 
and an SQ mass spectrometry detector. An Acquity UPLC BEH C18 column was used. 
The mobile phase was composed of water consisting of 0.1% formic acid (A) and 
acetonitrile (B). Each analysis ran for a total of 3 minutes. 
A Waters SQ mass spectrometer was used to ionize and detect natural product 
fractions. Both the positive and negative electrospray ionization (ESI) modes were used. 
The capillary voltage was set at 3.4kV and the extractor voltage was 2V. Nitrogen was 
used as the nebulizing gas. 130 °C was the set source temperature. The scan range was 
m/z 130-1400. OpenLynx was used for data processing by extracting all graphic 
information and converting it to text files to allow transfer to a database for storage and 
analysis (Tu et al. 2010). 
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Fractions were received from St. Jude Children’s Research Hospital at 2 mg/mL 
in DMSO and transferred to 384-well microplates along with drug controls. Organisms 
were obtained from the American Type Culture Collection in Manassas, VA and include 
the fungi Candida albicans ATCC 90028, Cryptococcus neoformans ATCC 90113, and 
Aspergillus fumigatus ATCC 204305. All organisms were tested using adjusted 
renditions of the Clinical and Laboratory Standards Institute (CLSI) methods. Optical 
density was used to monitor growth for all the organisms except for A. fumigatus 
(NCCLS 2002). Media augmented with 5% Alamar Blue
TM
 was used for growth 
detection of C. albicans and A. fumigatus (NCCLS 2006).  
The samples (1 μL), were serially-diluted and were transferred in duplicate to 
384-well flat bottom microplates. Inocula were prepared by correcting the OD630 of 
microbe suspensions in incubation broth [RPMI 1640/0.2% dextrose/0.03% 
glutamine/MOPS at pH 6.0 (Cellgro) for Candida spp., Sabouraud Dextrose for 
Cryptococcus neoformans, and 5% Alamar Blue
TM
/RPMI 1640 broth (0.2% dextrose, 
0.03% glutamine, buffered with 0.165M MOPS at pH 7.0) for A. fumigatus]. Fifty μL of 
each inoculum were added to the appropriate wells of the 384-well microplates using a 
Thermo Scientific Multidrop Combi. The drug control Amphotericin B was included in 
each assay.  
All organisms were read at either 530 nm using the Biotek Powerhouse XS Plate 
Reader or 544ex/590em (C. albicans and A. fumigatus) using the Polarstar Galaxy Plate 
Reader prior to and after incubation: Candida spp. at 35 °C for 24 hrs., C. neoformans at 
35 °C for 70-74 hrs., and A. fumigatus at 35 °C for 46-50 hrs.  
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During the primary analysis, samples were tested in duplicate at one test 
concentration (40 μg/mL) and percent inhibitions were calculated relative to blank and 
growth controls. Samples showing at least 50% or greater inhibition in at least one test 
organism were selected for dose response (secondary) studies using either 384- or 96-
well assays. During the secondary analysis, fractions were tested in duplicate at three test 
concentrations (5-fold dilutions). IC50s (concentrations that afford 50% inhibition relative 
to controls) were calculated using XLfit 4.2 software using fit model 201 to afford the 
concentration of the samples that inhibits the organism 50%. For isolated compounds, the 
minimum inhibitory concentration (MIC) is the lowest test concentration that prevents 
detectable growth (for A. fumigatus, no color change from blue to pink). Minimum 
fungicidal concentrations (MFC) were determined by removing 5 μL from each clear (or 
blue) well, transferring to fresh media and incubation as previously explained. The MFC 
is the lowest test concentration that kills the organism allowing no growth at all.       
 
Results 
There were a total of 13,787 fractions screened for % inhibition of various fungi. 
Out of these fractions, only 1,139 were confirmed to have antifungal activity using dose 
response (IC50). Eighteen of these confirmed active fractions were selected for LC-MS 
analysis based on the fact that little research had been conducted on the genus of these 
plant samples. Therefore, the extracts could potentially contain novel antifungal 
compounds. 
The lead coded as 80689-c4, derived from the leaves and stems of Hedera 
nepalensis (Araliaceae), was active against Candida albicans with an IC50 (half maximal 
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inhibitory concentration) of 8.11 µg/mL and against Cryptococcus neoformans with an 
IC50 of 9.00 µg/mL. This plant, which has the common name Nepal Ivy, was collected 
from the Missouri Botanical Garden in St. Louis, MO on September 19
th
 2005. Hedera 
nepalensis has been used medically as a diaphoretic and as a stimulant (Ummara et al. 
2013). The UPLC-MS-ELSD-PDA profiles are shown in Figure 1. The ELSD detection 
process accurately determines the proportionate amount of individual compounds in a 
mixture even if they are not UV active. Looking at the photodiode array (PDA) 
chromatogram, which measures the UV absorption of the sample, significant UV activity 
does not appear around the retention time of 1.50 min where the majority of the 
compounds found in this fraction are detected. 
The compound detected at the retention time 1.50 min showed an ion peak at 
751.3 m/z [M+H]
+
 in the (+)-ESIMS, indicating a molecular weight (MW) of 750 (Figure 
1e). This molecular weight was confirmed with the ion peak at 749.6 m/z [M-H]
-
 in the (-
-)-ESIMS, which also indicates a MW of 750 (Figure 1f). The compound was thus 
identified as Tauroside E with a MW of 750.96 m/z. This compound has been isolated 
from a plant of the Hedera genus and appears to have insignificant UV activity. 
Tauroside E has already been studied and found to have antifungal activity and is known 
to be produced in Hedera taurica (Shashkov et al. 1987). Therefore, it can be concluded 
that this compound is most likely the cause of 80689-c4’s antifungal activity. There is no 
further interest in the Hedera nepalensis plant as a novel antifungal drug source. 
 The lead coded 81069-c6, derived from the stems of Guapira fragrans 
(Nyctaginaceae), was active against Cryptococcus neoformans with an IC50 of 11.72  
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Figure 1: UPLC-MS-ELSD-PDA analysis of lead 80689-c4. (a) ELSD chromatogram; 
(b) PDA chromatogram; (c) and (d) positive and negative ESIMS total-ion 
chromatograms (TIC), respectively; (e) and (f) positive and negative ESIMS at retention 
time 1.50 min. 
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μg/mL. This plant sample was collected at the Missouri Botanical Garden on March 16th 
2006 and has the common name Four O’clock. Common uses for Guapira fragrans are 
generally unknown. The UPLC-MS-ELSD-PDA profiles are shown in Figure 2. 
The compound detected at the retention time 1.48 min showed an ion peak at 
284.8 m/z [M+H]
+
 in the (+)-ESIMS, indicating a molecular weight of 284 m/z (Figure 
2e). This MW was confirmed by the second peak in the (+)-ESIMS which gives a 
molecular weight of 569.0 m/z [2M+H]
+
. This second peak is twice the MW of the first 
indicating that a dimer was formed. An ion peak showing a molecular weight of 282.9 
m/z [M-H]
-
 can also be seen in the (--)-ESIMS at the same retention time (Figure 2f). 
There is a second peak at 567.1 m/z [2M-H]
-
 that again indicates a dimer was formed. A 
literature search for isolated compounds from the family Nyctaginaceae lead to the 
conclusion that the compound Wogonin was the one being detected. Wogonin has a 
molecular weight of 284.26 m/z, is UV active based on its conjugated system, and is 
known to have antifungal activity (Pal et al. 2003). Although little antifungal research has 
been conducted on the plant Guapira fragrans, this antifungal compound isolated from 
plants of the same family has a high probability of being found in this species as well. 
Therefore, isolation of the compound detected in this fraction of Guapira fragrans was 
deemed unnecessary.  
The lead coded 79880-c6, derived from the plant Oxytropis viscida (Fabaceae), 
was active against Cryptococcus neoformans with an IC50 of 4.5 μg/mL. This plant 
sample was collected at the Missouri Botanical Garden on June 15
th
 2005 and has the 
common name Sticky Crazyweed. The use of this plant is not widely known. The UPLC-
MS-ELSD-PDA profiles are shown in Figure 3.  
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Figure 2: UPLC-MS-ELSD-PDA analysis of lead 81069-c6. (a) ELSD 
chromatogram; (b) PDA chromatogram; (c) and (d) positive and negative ESIMS 
total-ion chromatograms (TIC), respectively; (e) and (f) positive and negative 
ESIMS at retention time 1.48 min. 
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Figure 3: UPLC-MS-ELSD-PDA analysis of lead 79880-c6. (a) ELSD 
chromatogram; (b) PDA chromatogram; (c) and (d) positive and negative ESIMS 
total-ion chromatograms (TIC), respectively; (e) and (f) positive and negative 
ESIMS at retention time 1.00 min. 
 
(f) (--)-ESIMS 
(1.48 min) 
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The compound detected at the retention time 1.00 min showed an ion peak at 
241.0 m/z [M+H]
+
 in the (+)-ESIMS, indicating a molecular weight of 240 m/z (Figure 
3e). This MW was confirmed in the (--)-ESIMS with an ion peak of 238.9 m/z [M-H]
-
, 
which also indicates a MW of 240 m/z (Figure 3f). A literature search determined that 
there were no compounds isolated from this family or genus of plant that have a MW of 
240 m/z. Thus, a scale-up bioassay-directed isolation was performed and confirmed the 
presence of an active compound with a MW of 240 m/z (Figure 3g). The isolated 
compound was determined to be trans-2’,4’-dihydroxychalcone with an IC50 of 1.06 
μg/mL, a MIC of 5 μg/mL, and a MFC of 5 μg/mL against Cryptococcus neoformans.  
 
Conclusion 
Through the use of modern technological advances like high-throughput 
screening, larger amounts of natural product extracts can be screened at one time saving 
time and resources. These improvements have resulted in increased interest in natural 
products as a source for antifungal drug discovery. To determine which natural products 
have the highest probability of containing a novel antifungal compound, LC-MS data 
analysis, literature research, and biological data are all used to prioritize plant samples. 
This process promotes dereplication (minimizing re-discovery) and further preserves 
valuable resources and time. 
The Hedera nepalensis fraction coded 80689-c4 was chosen for LC-MS data 
analysis because this plant sample produced active results during primary testing and no 
work on this plant had been found in literature pertaining to antifungal activity. The 
compound detected within the fraction had a molecular weight of around 750 m/z. Cross-
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referencing this molecular weight with compounds isolated from the Hedera genus in 
literature, the compound Tauroside E was found. Tauroside E has been isolated from the 
plant Hedera taurica (Shashkov et al. 1987). A second literature search was performed 
on the biological activity of this compound which was determined to be antifungal 
against Candida glabrata (Woodward et al. 1998). However, no work could be found on 
the effects of Tauroside E on other fungi, such as Candida albicans or Cryptococcus 
neoformans. Therefore, this high-throughput testing and LC-MS analysis has led to the 
discovery of the antifungal activity of the compound Tauroside E against additional 
species of fungi.  This compound was determined to be the cause of this fraction’s 
antifungal activity and there was no need to waste resources and time isolating the 
compound and performing further tests.  
The Guapira fragrans sample had similar results with literature research leading 
to the Wogonin compound isolated from the same family, Nyctaginaceae (Pal et al. 
2003). However, no evidence of compound isolation was found for the plant Guapira 
fragrans itself. Wogonin has been found to be antifungal against Aspergillus niger, 
Penicillium frequentance, P. notatum, and Botrytis cinerea. However, Wogonin has 
never before been confirmed to be antifungal against Cryptococcus neoformans.  
 The Oxytropis viscida fraction was found to have a compound of molecular 
weight around 240 m/z. The literature search determined that there was no compound of 
this molecular weight isolated from the same family or genus of Oxytropis viscida, 
warranting the isolation of the active fraction’s compound. The purified compound was 
then biologically tested and was found to be active against Cryptococcus neoformans. 
18 
 
 Using this high-throughput fractionation approach coupled with LC-MS data 
analysis, natural products can be efficiently prioritized for purification efforts. Novel 
antifungal compounds can be discovered with greater ease and with less required 
resources, time, and energy. This process also fuels dereplication efforts by preventing 
researchers from working on plant extracts or compounds that have already been 
extensively studied for antifungal activity. 
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